In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Millennium Makes Its Case as a Drug Developer

Executive Summary

Millennium claims to have an edge over Big Pharma and big biotechs: an evolved biology-driven approach to discovery and development derived from its roots in genomics, and a corporate culture based on integrating outside technologies that minimizes the Not-Invented-Here syndrome. Skeptics point to the fact that of the hundreds of targets it delivered to partners, none has resulted in a clinical candidate. Nonetheless, Millennium believes it now has a critical mass of knowledge about biological pathways that it can use for shrewd in-licensing and to choose those internal targets from which it will develop small-molecule drugs. But whether R&D proves to be a fertile source of internally discovered compounds or a sophisticated adjunct for licensing and development, Millennium's real challenge is to build a commercial organization and prioritize programs and capacity as it redirects its spending downstream.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts